mRNA's Future Beyond The COVID Vaccines
What learnings can mRNA/RNA therapeutics makers take away from the successes of the mRNA COVID vaccines and Alnylam’s Onpattro, the first LNP-delivered antisense oligonucleotide?
The rapid development, scale-up, and successful commercialization of mRNA vaccines served as a great case study on the important role mRNA/RNA therapeutics can play in society. However, for those striving to develop next-gen RNA therapeutics, achieving more specifically targeted non-viral delivery is a large hurdle to broadening these therapeutics’ applicability, durability, and effectiveness.
On October 4, 2022 Bioprocess Online Live hosted a panel discussion digging into the scientific-, development-, and business-related advancements that will enable the RNA therapeutics industry to meet the needs of a broader array of patient populations.
In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, unpack which learnings can be adapted from ASO-LNPs to mRNA/LNPs and from mRNA vaccines to mRNA therapeutics. They also touch upon which learnings cannot be neatly carried over from these previous success stories.
View the full presentation on-demand here.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.